ALLERGAN, Alcon Inc. and Bausch & Lomb Incorporated are dominating the Global Dry Eye Syndrome Treatment Market in 2019

Global Dry Eye Syndrome Treatment Market is expected to grow at a substantial CAGR of 6.8% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.

Access Full Report at https://databridgemarketresearch.com/reports/global-dry-eye-syndrome-treatment-market

The dry eye syndrome treatment market is a highly fragmented market which includes key players and local players. The market is growing owing to the favourable market scenario. The market has a prominent growth in upcoming years due to increasing prevalence of dry eye diseases, changing geographical trends, increasing awareness about diagnosis and treatment of the disease, rising geriatric population across the world and increase in Lasik surgery and usage of contact lenses.

The market has witnessed developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand. For instance, in May 2018, Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd, launched Teva-Cyclosporine. It is a generic version of Allergen’s Restasis. The major advantage of this product launch is that it will help the company in growing its market share in the dry eye treatment as more than 29.0% of Canada population suffers from the dry eye syndrome.

ALLERGAN dominated the dry eye syndrome treatment market.  The other key players existing in the market includes Alcon Inc. and Bausch & Lomb Incorporated, Mitotech, SA, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Novaliq GmbH, Prestige Consumer Healthcare, Inc., Horus Pharma, Senju Pharmaceutical Co. Ltd., VISUfarma, Akorn, Incorporated, Teva Pharmaceutical Industries Ltd., Santen Pharmaceutical Co., Ltd., Novartis AG, Similasan and others.

ALLERGAN:

ALLERGAN headquartered in Dublin, Ireland was incorporated in 2013. The company is focused on development, manufacturing and commercializing branded pharmaceutical, biologic, device, surgical and regenerative medicine products for patients around the world. The company mainly focuses on business segments namely, US Specialized Therapeutics, US General Medicine, International and other. The product related to the dry eye syndrome treatment market falls in the US Specialized Therapeutics segment. The increase in the net revenue in the US Specialized Therapeutics segment was mainly due to the LifeCell Acquisition and the Zeltiq Acquisition and the growth in Botox Therapeutics and Botox Cosmetics, which was partially offset by decrease in Restasis and the divestiture of the Medical Dermatology business.

  • In June 2019, Allergan participated at the Jefferies 2019 Healthcare Conference which was held in New York on 6th June. This would help the company to enhance its customer base.

It has its global networks through direct sales representatives and distributors in the North America, South America, Europe, Asia-Pacific, Middle East and Africa. The company has various subsidiaries such as ZELTIQ Aesthetics, Inc. (U.S.), Bonti, Inc. (U.S.), Allergan Medical (U.S.), Kythera Biopharmaceuticals, Inc. (U.S.), Oculeve, Inc. (U.S.) amongst others.

Alcon Inc.:

Alcon Inc. headquartered in Geneva, Switzerland was founded in 1945. The company is focuses on providing innovation technology to transform eye diseases and eye conditions. The company mainly manages their operations through the two main operating segments such as vision care and surgical.

The product related to the dry eye syndrome treatment market falls in the vision care sector. There is a significant increase in the sales of the vision care sector due to the growth in the contact lenses along with the continued double digit growth of the Dailies Total. Product categories of this company are surgical products, contact lens and lens care products, over-the-counter products for eye care.

  • In December 2018, Alcon Inc. acquired Tear Film Innovations, Inc. (U.S.). The major advantage of this acquisition is that it will help Alcon to expand its product portfolio in ocular health products and thus expanded its patient base by providing treatment for dry eye syndrome.

It has its global networks through direct sales representatives and distributors in North America, Europe, South America, Middle East, Asia-Pacific and Africa. It operates through its subsidiaries such as Alcon Pharmaceuticals Ltd. (Switzerland), Alcon Vision, LLC (U.S.) and Alcon Laboratories, Inc. (U.S.).

Bausch & Lomb Incorporated:

Bausch & Lomb Incorporated is headquartered in New York, U.S. and founded in 1853. The company is focused on offering the widest and finest range of eye health products including contact lenses and lens care products, pharmaceuticals, intraocular lenses and other eye surgery products. Product categories of this company include contact lens care, dry eye products, allergy/redness relief, Rx pharmaceuticals, eye wash, eye vitamins, surgical products, vision accessories, safety and industrial cleaning products, diagnostics.

  • In June 2018, Bausch + Lomb announced the launch of Soothe Xtra Protection (XP) Preservative Free lubricant eye drops by expanding the portfolio of the eye health products for meeting the rising demand for the dry eye symptoms relief without the usage of the preservatives. This will help the company to expand its product portfolio.

The company has wide geographical presence in North America, South America, Europe, Asia-Pacific and Middle East & Africa. It operates through its subsidiaries such as Bausch & Lomb U.K. Limited (U.K.), Bausch & Lomb Australia Pty Ltd (Australia), Bausch & Lomb Mexico, S.A. de C.V. (Mexico), Bausch & Lomb (Philippines), Inc. (Philippines), Bausch & Lomb Eyecare (India) Private Limited (India) among others.